Atrys is a biomedical company dedicated to provide diagnostic services and excelence medical treatments. It aims is to facilitate patients with individualized therapy, as well as to develop new therapeutic modalities and diagnostic tools.
The company was founded in 2007 by a group of doctors and cancer experts led by Dr. Carlos Cordon-Cardo, with the aim of providing a new model in the clinical management of cancer, by combining innovative and precise diagnostic techniques surgical and molecular pathology, along with new radiotherapy treatments.
The management team consists of scientists and senior managers with a solid career in the field of health. In total, Atrys has now 30 professionals specializing in oncology.
De Torres Sanahuja, Santiago - Executive President
Lozano Fernández, Isabel - CEO
Huch Ginesta, José María - CFO
Giró, Antonio - Managing Director Diagnostics
Isach, Marian Isach - Managing Director Oncology
Sánchez, Sara - Managing Director Prevention
Within the diagnostics business other than in the area of oncology, Atrys uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology and dermatology, using its own technology platform. This activity benefits Atrys's business relationship with stakeholders in the health sector, in a simmilar manner as in the field of oncology.
Research conducted by the team of Atrys in collaboration with international medical centers of academic excellence has produced results indicating that Single Dose high intensity radiation treatments allow to activate different biological mechanisms for tumor cure that are not activated with conventional radiotherapy.
The company model includes a molecular diagnostic methodology for individual tumor phenotyping that generates information that allows the specialist to identify which clinical approach is more appropriate for each patient and, in particular, to identify those who can benefit from the single-dose stereotactic body radiation therapy (SD-SBRT or Single dose radiotherapy).
Atrys is born with the mission to help people live healthier lives with a prolonged life expectancy.
To do this, it seeks to facilitate access to medical diagnosis and treatments of excellence, overcoming physical location barriers between doctor and patient specialist.
Atrys Health incrementa un 27,3% sus ingresos que ascienden a 202 millones de euros en el 2023
Atrys Health
Atrys Health y el Hospital Viamed Santa Elena se alían para el tratamiento del cáncer con un nuevo servicio en Oncología Médica
Atrys Health
Atrys alcanza un acuerdo para la venta de su área de negocio de compliance
Atrys Health
Atrys alcanza un acuerdo con Arraigo para la venta de Conversia, su área de negocio de compliance
Atrys Health
Atrys, pionera en la aplicación de un nuevo fármaco en cáncer de próstata en Portugal
Atrys Health
Atrys y Sant Joan de Déu inauguran el servicio de Medicina Nuclear, ubicado en el SJD Pediatric Cancer Center Barcelona
Atrys Health
El sector de la salud acelera su concentración: el 42% de las empresas planea una operación corporativa
Atrys Health
Atrys Health duplica su cifra de negocios en el primer semestre de 2022, hasta los 90,8 millones de euros
Atrys Health
Atrys completa con éxito una ampliación de capital de 72 millones de euros para impulsar su crecimiento
Atrys Health
Atrys obtiene en su centro IMOR la acreditación de excelencia de la Joint Commision International, el certificado de calidad más alto del mundo sanitario
Atrys Health
